Sign In
Buy AXSM
$233.49
+11.33 (+5.10%)
At Close: Jun 03, 2026
Why Axsome Therapeutics Stock Is Jumping Today
12:16pm, Monday, 26'th Apr 2021
The FDA granted Priority Review to the biotech's regulatory filing for its lead pipeline candidate.
Axsome Stock Jumps After Snagging Priority Review For Depression Drug
11:29am, Monday, 26'th Apr 2021
Axsome Therapeutics snagged a speedy review from the Food and Drug Administration for its depression treatment, known as AXS-05, on Monday, leading Axsome stock to gap higher. The post Axsome Stock Ju
AXSM Stock: Over 5% Increase Pre-Market Explanation
06:40am, Monday, 26'th Apr 2021
The stock price of Axsome Therapeutics, Inc. (NASDAQ: AXSM) increased by over 5% pre-market. This is why it happened.
FDA grants Priority Review and sets PDUFA action goal date of August 22, 2021
Why Is Axsome (AXSM) Down 19.9% Since Last Earnings Report?
12:07pm, Wednesday, 31'st Mar 2021
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
Axsome: Robust Fundamental Improvements
04:02pm, Thursday, 18'th Mar 2021
The crown jewel (AXS-05) is poised to gain its first FDA approval as a treatment for major depressive disorder.
Circling Back On Axsome Therapeutics
06:46pm, Tuesday, 02'nd Mar 2021
Axsome Therapeutics has been active in presenting its accomplishments in 2020 in recent days, making it a good time to update our investment thesis on this biopharma.
Axsome's (AXSM) Q4 Earnings Miss Estimates, Pipeline in Focus
10:37am, Tuesday, 02'nd Mar 2021
Axsome (AXSM) reports wider-than-expected loss in the fourth quarter of 2020. The company files an NDA for AXS-05 to treat major depressive disorder.
Axsome Therapeutics, Inc. (AXSM) CEO Herriot Tabuteau on Q4 2020 Results - Earnings Call Transcript
04:19pm, Monday, 01'st Mar 2021
Axsome Therapeutics, Inc. (AXSM) CEO Herriot Tabuteau on Q4 2020 Results - Earnings Call Transcript
Axsome Therapeutics to Present at Upcoming Investor Conferences
07:00am, Friday, 19'th Feb 2021
NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorder
Forget Bitcoin: This Biotech Stock Is a Better Buy in 2021
06:00am, Wednesday, 10'th Feb 2021
This company presents much more attractive prospects than the cryptocurrency.
Biotech Bonanza: COVID Launches Science at Warp Speed
07:41pm, Wednesday, 03'rd Feb 2021
From vaccines to diagnostics, the opportunities in biotechnology are rich for those who do their homework.
Is It Too Late to Get In On This Millionaire-Making Stock?
07:05am, Wednesday, 27'th Jan 2021
While it's already made some people rich, Axsome Therapeutics is just getting started.
Are Biotech Stocks a Good Idea Right Now?
10:22am, Thursday, 21'st Jan 2021
Take a look at a few trending biotech stocks and decide if this is something you want to invest in.
Implied Volatility Surging for Axsome Therapeutics (AXSM) Stock Options
09:47am, Thursday, 07'th Jan 2021
Investors need to pay close attention to Axsome Therapeutics (AXSM) stock based on the movements in the options market lately.
